InMed Pharmaceuticals Inc Share Price Deutsche Boerse AG
Equities
CA13764X1069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
14/05 | Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M | MT |
14/05 | InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Sales 2024 * | 7.3M 5.33M 4.87M 445M | Sales 2025 * | 9.12M 6.66M 6.09M 556M | Capitalization | 3.26M 2.38M 2.18M 199M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.45 x |
Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | 0.36 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.42% |
Latest transcript on InMed Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16/16/16 |
Chief Operating Officer | - | 05/18/05 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 11/22/11 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16/16/16 |
Andrew Hull
CHM | Chairman | 61 | 12/16/12 |
1st Jan change | Capi. | |
---|---|---|
+20.34% | 126B | |
+23.05% | 118B | |
+23.26% | 27.87B | |
-18.46% | 20.95B | |
-15.13% | 16.92B | |
-13.56% | 16.18B | |
+10.19% | 14.84B | |
-46.10% | 14.79B | |
+51.58% | 14.08B |